The GLP-1 Pioneer
Ozempic and Wegovy made Novo Europe's most valuable company — and they can't make enough
GLP-1 Revenue
Ozempic + Wegovy revenue (billions)
GLP-1 Revenue
$36B
GLP-1 Share of Revenue
The transformation of Novo Nordisk
Share
85.0%
The Ozempic Empire
A Danish company now worth more than the entire Danish stock market
$500B+
Novo Nordisk value
vs
$400B
Denmark GDP
A single Danish company is now worth more than the entire Danish economy.
NVONYSE
Novo Nordisk A/S
Danish pharma reshaping healthcare — Ozempic, Wegovy
$42.92
+47588.9% since 1981
Revenue (TTM)
How much money came in the door over the past year. Think of it as total sales before paying any bills.
$41.5B
+28.5%
Net Income (TTM)
What's left after paying everyone—employees, suppliers, taxes, everything. This is the actual profit.
$16.6B
+37.9%
Gross Margin
For every dollar of sales, how much is left after making the product? Higher is better—more room for profit.
89.0%
EPS (TTM)
If you owned one share, this is your slice of the profit. Bigger number = more earnings for each share you hold.
$7.24
+37.9%
Financial Performance
Semaglutide dominates GLP-1 market with 50%+ share. Operating margins above 40%. Demand so high they literally cannot make enough product.
Revenue
Money coming in the door each quarter—total sales before paying any bills.
$10.8B
+158.3%
Net Income
What's left after paying everyone. This is the real profit the company keeps.
$4.4B
+227.4%
Earnings Per Share
Your slice of the profit for each share you own. Bigger = better.
$1.92
+231.0%
Margins
How much profit is made on each dollar of sales. Higher margins = more efficient business.
Profitability over time
Gross
89.0%
Operating
49.5%
Enjoyed the Novo Nordisk A/S breakdown?
Get the next one in your inbox.
About Novo Nordisk A/S
Novo Nordisk is a Danish pharmaceutical company specializing in diabetes care. The maker of Ozempic and Wegovy, it has become Europe's most valuable company and is worth more than Denmark's entire GDP, driven by unprecedented demand for GLP-1 medications.
HealthcarePharmaceuticals
Data Sources
Price Data: Yahoo FinanceFinancials: Novo Nordisk A/S SEC Filings